A comparison of ceftazidime and tobramycin in the treatment of complicated urinary tract infections.
Sixty-two patients with complicated urinary tract infections were treated by random allocation with either ceftazidime (0.5 g every 12 h) or tobramycin (3 mg/kg/day). All patients had underlying urological conditions and a urinary tract infection with an organism sensitive to both ceftazidime and tobramycin. Thirty-two patients received tobramycin and 30 patients received ceftazidime. Thirty-two of the infections were caused by Pseudomonas spp., 16 by Escherichia coli, and the remainder by various Gram-negative organisms. Cure rates were approximately 85% in both treatment groups and side effects were minimal.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002442:Ceftazidime; D002511:Cephalosporins / Q000627:therapeutic use*; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy; D011897:Random Allocation; D014031:Tobramycin / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D002511:Cephalosporins; D002442:Ceftazidime; D014031:Tobramycin